Skip to main content

Table 1 Clinical characteristics of emphysema patients and control individuals with and without AAT-deficiency.

From: Circulating monocytes from healthy individuals and COPD patients

Subject group characteristics Control subjects M-AAT n= 20 Healthy subjects Z-AAT n = 10 COPD patients Z-AAT n = 10 COPD patients M-AAT n = 10
Male/Female 11/9 5/5 5/5 5/5
Age (years) 53 ± 9.6 47.4 ± 11 57 ± 12 59.4 ± 6.7
Smoking history:     
Never smokers 9 6 3 0
Exsmokersa 10 3 6 8
Smokers b 1 1 1 2
FEV1 % of predictedc 95.9 ± 17 94 ± 12 43 ± 13 37 ± 16
FVC % of predicted 92.8 ± 17 94 ± 14 63 ± 12 50 ± 15
FEV1/FVC% ratio 76 ± 8 77 ± 10 50 ± 15 40 ± 20
Medication     
No medication 20 6 - -
Inhaled corticosteroids - 3 7 10
Bronchodilatators - - 10 8
Diuretics - - 3 3
Continuous oxygen - - 1 1
Anti-inflammatory - - - -
Anti-depressants - 1 - 1
  1. a – exsmokers, stopped smoking at least 3 month before the study. b – current smokers. c – measured after bronchodilatation (terbutaline (1 mg)). Values are expressed as mean ± SD.